Trial reportNature2022
Genomics to select treatment for patients with metastatic breast cancer.
Abstract readRandomized Controlled Trial
In one paragraph
Trial report in Nature, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 98 papers, 2 of them syntheses that pooled it.
0numbers the graph read from it
0cells of the map it votes in
98citing papers in PubMed, 2 pooled it
14.5field-weighted citation impact, top 1% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
98 citing papers in PubMed, 2 syntheses or guidelines pooled it, 160 citations in OpenAlex.
- Molecular Tumor Boards clinical impact on patient care and structural features: A systematic review and meta-analysis.PLoS medicine · 2026Pooled it
- Next-generation sequencing for guiding matched targeted therapies in people with relapsed or metastatic cancer.The Cochrane database of systematic reviews · 2025Pooled it
- Genomically matched therapy in advanced solid tumors: the randomized phase 2 ROME trial.Nature medicine · 2025Trial
- CK2 in triple-negative breast cancer: oncogenic signaling networks and emerging CK2 inhibitor-based combination therapies.Clinical and experimental medicine · 2026Review
- Case report of invasive lobular carcinoma with pineal metastasis.Oxford medical case reports · 2026Article
- Harnessing Proteogenomics to Advance Precision Oncology: From Melanoma and Hepatocellular Carcinoma Perspective.Current oncology reports · 2026Review
- Real-world clinical utility of tumor whole-genome sequencing in solid cancers.Nature medicine · 2026Article
- New Perspectives in the Management of Triple-Negative Breast Cancer.Breast care (Basel, Switzerland) · 2026Review
- Delivering precision oncology in metastatic breast cancer: Clinical impact of comprehensive genomic profiling-The CATCH experience.International journal of cancer · 2026Article
- Integration of RNA Editing into Multiomics Machine Learning Models for Predicting Drug Responses in Breast Cancer Patients.Biomedicines · 2026Article
- Molecular Profiling for Precision Oncology: Moving Beyond Feasibility and Safety.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2026Article
- Tumor genomics in patients younger than 40 years of age with metastatic breast cancer.NPJ precision oncology · 2026Article
- Real-world clinical utility of comprehensive genomic profiling in advanced solid tumors.Nature medicine · 2026Article
- The impact of AI on modern oncology from early detection to personalized cancer treatment.NPJ precision oncology · 2026Review
- Multidimensional mapping of stimulation-responsive regulatory elements and candidate causal variants in T cell activation.Science advances · 2026Article
- Selected Pathological Criteria That Predict Low Rates of Axillary Lymph Node Metastases Regardless of Patient Age: A Single Institution Study.The breast journal · 2026Article
- Endocrine therapy resistance of breast cancer: Important role of G protein-coupled estrogen receptor (GPER) and new therapeutic strategies.Genes & diseases · 2026Review
- Next-generation sequencing methodologies to identify patients for targeted therapy: focus on HR+/HER2- metastatic breast cancer.Pathologica · 2025Review
- AI-identified CD133-targeting natural compounds demonstrate differential anti-tumor effects and mechanisms in pan-cancer models.EMBO molecular medicine · 2025Article
- Perceived Barriers to NGS-Based Molecular Profiling Among US Metastatic Breast Cancer Patients.Diagnostics (Basel, Switzerland) · 2025Article
38 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
- Commented on by
Authors and funding
39 authors at 19 institutions in 2 countries.
Fabrice Andre *Department of Medical Oncology, Gustave Roussy, Villejuif, France. fabrice.andre@gustaveroussy.fr.ORCID http://orcid.org/0000-0001-5795-8357
Thomas Filleron *Department of Biostatistics, Institut Claudius Regaud, IUCT oncopole, Toulouse, France.
Maud Kamal *Department of Drug Development and Innovation, Institut Curie, Saint Cloud, France.
Fernanda MoseleINSERM U981, Gustave Roussy, Villejuif, France.
Monica ArnedosDepartment of Medical Oncology, Gustave Roussy, Villejuif, France.
Florence DalencDepartment of Medical Oncology, Institut Claudius-Regaud IUCT oncopole and University of Paul Sabatier, Toulouse, France.
Marie-Paule SablinDepartment of Drug Development and Innovation, Institut Curie, Saint Cloud, France.
Mario CamponeInstitut de Cancérologie de l'Ouest - René Gauducheau, Saint Herblain, University of Angers, Angers, France.
Hervé BonnefoiDepartment of Medical Oncology, Institut Bergonié INSERM U1218 and Université of Bordeaux, Bordeaux, France.
Claudia Lefeuvre-PlesseDepartment of Medical Oncology, Centre Eugène Marquis, Rennes, France.
William JacotDepartment of Medical Oncology, Institut du Cancer de Montpellier, Institut de Recherche en Cancérologie de Montpellier INSERM U1194 and Montpellier University, Montpellier, France.ORCID http://orcid.org/0000-0001-7834-061X
Florence CoussyDepartment of Medical Oncology, Institut Curie, Saint-Cloud, France.
Jean-Marc FerreroDepartment of Medical Oncology, Centre Antoine Lacassagne, University Côte d'Azur, Nice, France.
George EmileDepartment of Medical Oncology, Centre François Baclesse, Caen, France.
Marie-Ange Mouret-ReynierDepartment of Medical Oncology, Centre Jean Perrin, Clermont-Ferrand, France.
Jean-Christophe TheryDepartment of Medical Oncology, Centre Hennri Becquerel, University of Medicine of Rouen, Rouen, France.
Nicolas IsambertDepartment of Medical Oncology, Centre Georges François Leclerc, Dijon, France.
Alice MegeInstitut Sainte Catherine, Avignon, France.
Philippe BarthelemyInstitut de Cancérologie Strasbourg Europe, Strasbourg, France.
Benoit YouDepartment of Medical Oncology, Institut de Cancérologie des Hospices Civils de Lyon, Université Claude Bernard Lyon 1, Lyon, France.ORCID http://orcid.org/0000-0002-3177-8857
Nawale HajjajiDepartment of Medical Oncology, Centre Oscar Lambret INSERM U1192 PRISM Laboratory and University of Lille, Lille, France.
Ludovic LacroixCancer Genetics Laboratory, Department of Pathology and Medical Biology, Gustave Roussy, Villejuif, France.
Etienne RouleauCancer Genetics Laboratory, Department of Pathology and Medical Biology, Gustave Roussy, Villejuif, France.
Alicia Tran-DienINSERM U981, Gustave Roussy, Villejuif, France.
Sandrine BoyaultDepartment of Translational Research and Innovation, Centre Léon Bérard, Lyon, France.ORCID http://orcid.org/0000-0002-2297-6894
Valery AttignonDepartment of Translational Research and Innovation, Centre Léon Bérard, Lyon, France.
Pierre GestraudBioinformatics and Computational Systems Biology of Cancer, PSL Research University, Mines Paris Tech, INSERM U900, Paris, France.ORCID http://orcid.org/0000-0002-3893-9879
Nicolas ServantBioinformatics and Computational Systems Biology of Cancer, PSL Research University, Mines Paris Tech, INSERM U900, Paris, France.ORCID http://orcid.org/0000-0003-1678-7410
Christophe Le TourneauDepartment of Drug Development and Innovation, Institut Curie, Saint Cloud, France.ORCID http://orcid.org/0000-0001-9772-4686
Linda Larbi CherifDepartment of Drug Development and Innovation, Institut Curie, Saint Cloud, France.
Isabelle SoubeyranUnit of Molecular Pathology - Department of Biopathology, Institut Bergonié, Bordeaux, France.
Filippo MontemurroCandiolo Cancer Institute, FPO-IRCCS, Candiolo, Italy.ORCID http://orcid.org/0000-0003-4231-2291
Alain MorelDepartment of Innate Immunity and Immunotherapy, Institut de Cancérologie de l'Ouest - Centre Paul Papin, Angers, France.
Amelie LusqueDepartment of Biostatistics, Institut Claudius Regaud, IUCT oncopole, Toulouse, France.
Marta JimenezUnicancer, Paris, France.ORCID http://orcid.org/0000-0002-4233-8478
Alexandra JacquetUnicancer, Paris, France.ORCID http://orcid.org/0000-0001-6377-2487
Anthony GonçalvesDepartment of Medical Oncology, Institut Paoli-Calmettes, Marseille, France.
Thomas BachelotDepartment of Medical Oncology, Centre Léon Bérard, Lyon, France.
Ivan BiecheDepartment of Genetics, Institut Curie, INSERM U1016, Université Paris Cité, Paris, France.
Inserm · FRInstitut Curie · FRCentre Léon Bérard · FRInstitut Gustave Roussy · FRInstitut Claudius Regaud · FRInstitut de Cancérologie de l'Ouest · FRUniCancer Group · FRCandiolo Cancer Institute · ITCentre Antoine Lacassagne · FRCentre Eugène Marquis · FRCentre François Baclesse · FRCentre Georges François Leclerc · FRCentre Jean Perrin · FRInstitut Bergonié · FRInstitut de Cancérologie Strasbourg · FRInstitut Paoli-Calmettes · FRInstitut Sainte Catherine · FRUniversité Claude Bernard Lyon 1 · FRUniversité Toulouse III - Paul Sabatier · FR
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cancer progression is driven in part by genomic alterations
Indexed as
Breast NeoplasmsClinical Decision-MakingGenome, HumanGenomicsNeoplasm MetastasisDisease ProgressionDNA Mutational AnalysisFemaleGenes, BRCA1Genes, BRCA2HumansPhthalazinesPiperazinesolaparibPhthalazinesPiperazines
Identifiers
What Socratic holds
Textmetadata
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.